- Home
- PTON vs IBRX Comparison
PTON vs IBRX Comparison
Compare PTON & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTON
- IBRX
- Stock Information
- Founded
- PTON 2012
- IBRX 2014
- Country
- PTON United States
- IBRX United States
- Employees
- PTON N/A
- IBRX N/A
- Industry
- PTON Recreational Games/Products/Toys
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTON Consumer Discretionary
- IBRX Health Care
- Exchange
- PTON Nasdaq
- IBRX Nasdaq
- Market Cap
- PTON 2.7B
- IBRX 2.4B
- IPO Year
- PTON 2019
- IBRX N/A
- Fundamental
- Price
- PTON $6.16
- IBRX $2.07
- Analyst Decision
- PTON Buy
- IBRX Strong Buy
- Analyst Count
- PTON 19
- IBRX 5
- Target Price
- PTON $7.72
- IBRX $11.35
- AVG Volume (30 Days)
- PTON 12.8M
- IBRX 8.7M
- Earning Date
- PTON 05-08-2025
- IBRX 05-16-2025
- Dividend Yield
- PTON N/A
- IBRX N/A
- EPS Growth
- PTON N/A
- IBRX N/A
- EPS
- PTON N/A
- IBRX N/A
- Revenue
- PTON $2,527,400,000.00
- IBRX $14,745,000.00
- Revenue This Year
- PTON N/A
- IBRX $579.28
- Revenue Next Year
- PTON N/A
- IBRX $179.96
- P/E Ratio
- PTON N/A
- IBRX N/A
- Revenue Growth
- PTON N/A
- IBRX 2270.58
- 52 Week Low
- PTON $2.83
- IBRX $1.83
- 52 Week High
- PTON $10.90
- IBRX $9.16
- Technical
- Relative Strength Index (RSI)
- PTON 45.31
- IBRX 36.78
- Support Level
- PTON $5.82
- IBRX $1.83
- Resistance Level
- PTON $7.11
- IBRX $2.63
- Average True Range (ATR)
- PTON 0.43
- IBRX 0.19
- MACD
- PTON 0.04
- IBRX -0.05
- Stochastic Oscillator
- PTON 44.32
- IBRX 23.08
About PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of bike and tread and related accessories sales, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue is generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from the International markets.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.